Adverum Biotechnologies reported positive 52-week data from the phase 2 LUNA trial as well as long-term follow-up results from the OPTIC trial of Ixo-vec in patients with wet age-related macular degeneration.
“Today’s clinical updates underscore Ixo-vec’s potential best-in-class product profile in wet AMD and highlight that we have essentially de-risked our phase 3 pivotal program,” Laurent Fischer, CEO of Adverum, told Healio. “We’ve consistently demonstrated best-in-industry clinical activity, and with our phase 2 LUNA study, we’ve shown to continue